Donald Gardner, MD
Endocrinology · Houston, TXNPI 1174616619
Payments from drug & device makers
Across 711 payments — averaging $9950.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$6.1M
- Amgen$600K
- AstraZeneca$267K
- Sanofi US Services Inc.$99K
- AbbVie$25K
- Eli Lilly Export S.A. Puerto Rico Branch$8K
- plus $13K from 44 others
Across 16 payments — averaging $6497.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$104K
What the payments were for
- Travel & lodging$1,0798%
- Food & beverage$11,42390%
- Education$1361%
- Gifts$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$328
- Ozempic$157
- DEXCOM G6 TRANSMITTER$115
How this compares
Too few endocrinology providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 357 | $604,066 |
| MounjaroTirzepatide | 234 | $320,075 |
| JardianceEmpagliflozin | 201 | $243,529 |
| TrulicityDulaglutide | 99 | $151,233 |
| RybelsusSemaglutide | 99 | $138,663 |
| FarxigaDapagliflozin Propanediol | 99 | $126,119 |
| Tresiba Flextouch U-100Insulin Degludec | 126 | $82,535 |
| JanuviaSitagliptin Phosphate | 70 | $81,713 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 58 | $69,200 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $53,359 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $53,254 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $50,533 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 82 | $42,289 |
| Repatha SureclickEvolocumab | 22 | $26,929 |
| Humalog Kwikpen U-100Insulin Lispro | 103 | $23,316 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $1,274 | $766,238492 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,691 | $486,554384 claims |
| Boehringer IngelheimJardiance, Tradjenta | $612 | $264,265216 claims |
| AstraZenecaFarxiga | $266,660 | $126,11999 claims |
| MerckJanuvia, Janumet | $226 | $88,09181 claims |
| NovartisSandostatin Lar Depot | $223 | $53,25412 claims |
| AbbVieSynthroid, Armour Thyroid | $24,675 | $21,849306 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $236 | $8,355761 claims |
| Sanofi-aventis U.S. LLCLantus | $637 | $2,91012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Texason file to place this against a meaningful peer group, so we don't.
Other endocrinology in Houston
- Basma AtaallahHouston$950
- Eric DealHouston$0
- Scott CarlsonHouston$0
- Claudia Ramirez BustamanteHouston$0
- Morali SharmaHouston$0
- Paras MehtaHouston$0
- Israel HartmanArlington$529K
- David FeinsteinDallas$10K
- Jaime CastroFort Worth$8K
- Uma GunasekaranDallas$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.